Survival in 12,653 breast cancer patients with extensive axillary lymph node metastasis in the anthracycline era

Shannon H. Beal, Steve R. Martinez, Robert J Canter, Steven L. Chen, Vijay P. Khatri, Richard J Bold

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Institutional data are conflicting regarding the prognosis of breast cancer patients with extensive (≥10) axillary lymph node (ALN) metastases. We hypothesized that overall survival (OS) and disease specific survival (DSS) improved after the introduction of anthracyclinebased therapy in 1997. We used the Surveillance, Epidemiology, and End results (SEER) database to identify breast cancer patients with ≥10 ALN metastases diagnosed between 1988 and 2004. Patients were categorized according to whether they were diagnosed prior to the FDA approval of anthracyclines (pre-anthracycline era, pre-AE) or after approval (post-anthracycline era, post-AE). Univariate analyses of OS and DSS were performed using the Kaplan-Meier method and differences assessed via the log rank test. Anthracycline era as an independent predictor of OS and DSS was evaluated using Cox proportional hazards models with patient age, hormone receptor status, tumor size, use of radiation therapy, and number of metastatic ALNs as covariates. Entry criteria were met by 12,653 patients. Of these, 5,655 (44.7%) and 6,998 (55.3%) were treated in the pre-AE and post-AE, respectively. On univariate analysis, post-AE patients experienced significantly improved rates of OS (P<0.001) and DSS (P<0.001) relative to pre-AE patients. On multivariate analysis, treatment in the post-AE favorably influenced both OS (Hazard Ratio [HR] 0.90, 95% Confidence Interval [CI] 0.84-0.96) and DSS (HR 0.84, CI 0.79-0.91). Both OS and DSS are poor in patients with extensive ALN metastases. Patients with advanced breast cancer treated in the post-AE demonstrated superior OS and DSS.

Original languageEnglish (US)
Pages (from-to)1420-1424
Number of pages5
JournalMedical Oncology
Volume27
Issue number4
DOIs
StatePublished - Dec 2010

Fingerprint

Anthracyclines
Lymph Nodes
Breast Neoplasms
Neoplasm Metastasis
Survival
Confidence Intervals
Survival Analysis
Proportional Hazards Models
Epidemiology
Radiotherapy
Multivariate Analysis
Survival Rate
Databases
Hormones

Keywords

  • Advanced breast cancer
  • Anthracycline
  • SEER
  • Survival

ASJC Scopus subject areas

  • Oncology
  • Cancer Research
  • Hematology

Cite this

Survival in 12,653 breast cancer patients with extensive axillary lymph node metastasis in the anthracycline era. / Beal, Shannon H.; Martinez, Steve R.; Canter, Robert J; Chen, Steven L.; Khatri, Vijay P.; Bold, Richard J.

In: Medical Oncology, Vol. 27, No. 4, 12.2010, p. 1420-1424.

Research output: Contribution to journalArticle

Beal, Shannon H. ; Martinez, Steve R. ; Canter, Robert J ; Chen, Steven L. ; Khatri, Vijay P. ; Bold, Richard J. / Survival in 12,653 breast cancer patients with extensive axillary lymph node metastasis in the anthracycline era. In: Medical Oncology. 2010 ; Vol. 27, No. 4. pp. 1420-1424.
@article{df93c98b41204aa1a11d382555972081,
title = "Survival in 12,653 breast cancer patients with extensive axillary lymph node metastasis in the anthracycline era",
abstract = "Institutional data are conflicting regarding the prognosis of breast cancer patients with extensive (≥10) axillary lymph node (ALN) metastases. We hypothesized that overall survival (OS) and disease specific survival (DSS) improved after the introduction of anthracyclinebased therapy in 1997. We used the Surveillance, Epidemiology, and End results (SEER) database to identify breast cancer patients with ≥10 ALN metastases diagnosed between 1988 and 2004. Patients were categorized according to whether they were diagnosed prior to the FDA approval of anthracyclines (pre-anthracycline era, pre-AE) or after approval (post-anthracycline era, post-AE). Univariate analyses of OS and DSS were performed using the Kaplan-Meier method and differences assessed via the log rank test. Anthracycline era as an independent predictor of OS and DSS was evaluated using Cox proportional hazards models with patient age, hormone receptor status, tumor size, use of radiation therapy, and number of metastatic ALNs as covariates. Entry criteria were met by 12,653 patients. Of these, 5,655 (44.7{\%}) and 6,998 (55.3{\%}) were treated in the pre-AE and post-AE, respectively. On univariate analysis, post-AE patients experienced significantly improved rates of OS (P<0.001) and DSS (P<0.001) relative to pre-AE patients. On multivariate analysis, treatment in the post-AE favorably influenced both OS (Hazard Ratio [HR] 0.90, 95{\%} Confidence Interval [CI] 0.84-0.96) and DSS (HR 0.84, CI 0.79-0.91). Both OS and DSS are poor in patients with extensive ALN metastases. Patients with advanced breast cancer treated in the post-AE demonstrated superior OS and DSS.",
keywords = "Advanced breast cancer, Anthracycline, SEER, Survival",
author = "Beal, {Shannon H.} and Martinez, {Steve R.} and Canter, {Robert J} and Chen, {Steven L.} and Khatri, {Vijay P.} and Bold, {Richard J}",
year = "2010",
month = "12",
doi = "10.1007/s12032-009-9396-4",
language = "English (US)",
volume = "27",
pages = "1420--1424",
journal = "Medical Oncology",
issn = "1357-0560",
publisher = "Humana Press",
number = "4",

}

TY - JOUR

T1 - Survival in 12,653 breast cancer patients with extensive axillary lymph node metastasis in the anthracycline era

AU - Beal, Shannon H.

AU - Martinez, Steve R.

AU - Canter, Robert J

AU - Chen, Steven L.

AU - Khatri, Vijay P.

AU - Bold, Richard J

PY - 2010/12

Y1 - 2010/12

N2 - Institutional data are conflicting regarding the prognosis of breast cancer patients with extensive (≥10) axillary lymph node (ALN) metastases. We hypothesized that overall survival (OS) and disease specific survival (DSS) improved after the introduction of anthracyclinebased therapy in 1997. We used the Surveillance, Epidemiology, and End results (SEER) database to identify breast cancer patients with ≥10 ALN metastases diagnosed between 1988 and 2004. Patients were categorized according to whether they were diagnosed prior to the FDA approval of anthracyclines (pre-anthracycline era, pre-AE) or after approval (post-anthracycline era, post-AE). Univariate analyses of OS and DSS were performed using the Kaplan-Meier method and differences assessed via the log rank test. Anthracycline era as an independent predictor of OS and DSS was evaluated using Cox proportional hazards models with patient age, hormone receptor status, tumor size, use of radiation therapy, and number of metastatic ALNs as covariates. Entry criteria were met by 12,653 patients. Of these, 5,655 (44.7%) and 6,998 (55.3%) were treated in the pre-AE and post-AE, respectively. On univariate analysis, post-AE patients experienced significantly improved rates of OS (P<0.001) and DSS (P<0.001) relative to pre-AE patients. On multivariate analysis, treatment in the post-AE favorably influenced both OS (Hazard Ratio [HR] 0.90, 95% Confidence Interval [CI] 0.84-0.96) and DSS (HR 0.84, CI 0.79-0.91). Both OS and DSS are poor in patients with extensive ALN metastases. Patients with advanced breast cancer treated in the post-AE demonstrated superior OS and DSS.

AB - Institutional data are conflicting regarding the prognosis of breast cancer patients with extensive (≥10) axillary lymph node (ALN) metastases. We hypothesized that overall survival (OS) and disease specific survival (DSS) improved after the introduction of anthracyclinebased therapy in 1997. We used the Surveillance, Epidemiology, and End results (SEER) database to identify breast cancer patients with ≥10 ALN metastases diagnosed between 1988 and 2004. Patients were categorized according to whether they were diagnosed prior to the FDA approval of anthracyclines (pre-anthracycline era, pre-AE) or after approval (post-anthracycline era, post-AE). Univariate analyses of OS and DSS were performed using the Kaplan-Meier method and differences assessed via the log rank test. Anthracycline era as an independent predictor of OS and DSS was evaluated using Cox proportional hazards models with patient age, hormone receptor status, tumor size, use of radiation therapy, and number of metastatic ALNs as covariates. Entry criteria were met by 12,653 patients. Of these, 5,655 (44.7%) and 6,998 (55.3%) were treated in the pre-AE and post-AE, respectively. On univariate analysis, post-AE patients experienced significantly improved rates of OS (P<0.001) and DSS (P<0.001) relative to pre-AE patients. On multivariate analysis, treatment in the post-AE favorably influenced both OS (Hazard Ratio [HR] 0.90, 95% Confidence Interval [CI] 0.84-0.96) and DSS (HR 0.84, CI 0.79-0.91). Both OS and DSS are poor in patients with extensive ALN metastases. Patients with advanced breast cancer treated in the post-AE demonstrated superior OS and DSS.

KW - Advanced breast cancer

KW - Anthracycline

KW - SEER

KW - Survival

UR - http://www.scopus.com/inward/record.url?scp=79951775269&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79951775269&partnerID=8YFLogxK

U2 - 10.1007/s12032-009-9396-4

DO - 10.1007/s12032-009-9396-4

M3 - Article

VL - 27

SP - 1420

EP - 1424

JO - Medical Oncology

JF - Medical Oncology

SN - 1357-0560

IS - 4

ER -